Genetic analysis has led to the successful diagnosis and treatment of a young girl with Progressive Dystonia. The girl, unable to speak or move, is now able to move around, speak, laugh, and play.
The FDA has approved Seattle Genetics’ Hodgkin’s lymphoma treatment, which is the first to be approved to treat the disease in over 40 years.
Experts have revealed that cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80% of the British market since launching last year, saving the healthcare system £80 million a year.
Going against industry trend of backing out of the neuroscience field, is Celgene, who is about to put down a potential $2.2 million to gain options on three Prothena drug candidates.
Chinese pharmaceutical companies are proving their place in the US generic drugs market, with a rising number of approvals for copycat medicines almost doubling in the past year.
Scott Gottlieb, head of the Food and Drug Administration (FDA) has revealed that a “rigged payment scheme” between drug plans, insurers and pharmaceutical companies has blocked access to less-expensive versions of some of the most expensive drugs in the U.S.
To unearth new functional regions in the human genome with potential roles in shaping clinically important traits, researchers are using animals with extraordinary traits to reveal new elements.
Biological drugs are complex molecules made in living cells, and they have changed medicine in the past two decades, offering rich choices for companies making almost identical copies as patents expire.
Last year, insiders said that Pfizer considered whether to sell, spin off or keep its Consumer Healthcare Business. Now, those same insiders say Johnson & Johnson has decided it’s no longer interested.
Sick and tired of dealing with generic drug shortages and unpredictable price increases, five large U.S. health systems are taking an unusual step: they’re forming their own nonprofit generic drugmaker.